DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That competition is cutting into demand for Novo Nordisk’s prescriptions, a ...

Don't want to spend a fortune and break the bank on investing in growth stocks? If you're looking for cheap growth stocks to ...

Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known as GLP-1s, are changing how Americans shop for groceries. In early January, Food & Wine published a story about ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications, which suppress appetite and reduce food consumption. GLP-1 drugs, popular for weight loss, are expected to ...

However, a new class of medications, GLP-1 agonists, originally designed for diabetes and obesity management, shows promise as a revolutionary tool in addiction treatment. GLP-1, or glucagon-like ...

GLP-1 drugs, or GLP-1 receptor agonists, were originally solely intended for use as diabetes medications. However, they are now being used for a variety of purposes, including helping people with ...

It’s a synthetic version of the hormone GLP-1, which helps regulate our metabolism and hunger. Semaglutide and other newer GLP-1 medications have proven to be far more effective at treating ...

Popular medications to treat diabetes, heart disease and obesity may offer a wider range benefits and some risks, according to a new "big data" study.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...